EN DE
Watch Phaos Technology Holdings for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Phaos Technology Holdings (POAS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Phaos Technology Holdings stock $0.69, price $0.77, that is 9.5% below the price, quality 21 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Singapore · ISIN KYG7049C1042

PT Phaos Technology Holdings logo Thin data Nov 10, 2026

Phaos Technology Holdings

POAS · US
Weak valuation

Our calculation puts a fair price 10% below what the stock costs today.

Low debt
Revenue last quarter 58% below a year ago.
Fair value $0.6938 · Overvalued
Quality 21/100
Weak Growth (revenue 3y −41.2 %/yr in USD)
Negative free cash flow
Trails peers (3/8)
Narrow moat 8/100 · thin data
Thin data
Estimate
Watch Phaos Technology Holdings for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$99.00 $0.7300 Fair Value $0.6938 Nov 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

12‑month range $0.7300 – $99.00 · fair‑value band $0.5203 – $0.8672 · the $0.7670 price screens above the $0.6938 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Phaos Technology in your weekly email

Every Wednesday you see whether Phaos Technology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Phaos Technology Holdings (Cayman) Limited, through its subsidiary, Phaos Technology Pte. Ltd., engages in the manufacturing and commercialization of advanced microscopy-related solutions, technologies, and products in Singapore.

Show moreShow less

The company offers Optonano that enables users to view live and still images for construction of high-quality image of larger sample areas; PT-Industrial for use in material study, failure analysis, simple measuring, quality control, inspection, and manufacturing; and PT-Metrology, which provides dimensional measurements with a single key operation.

It also provides PT-Biology to create specialized images needed in the biomedical sector; PT-Stereo, a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples; and PT-Zoom that offers three-dimensional magnified view of samples to enhance visualization.

In addition, the company offers software. The company serves manufacturing companies; biomedical service providers; and research and development institutions. The company was founded in 2017 and is based in Singapore.

Stock analysis

Phaos Technology Holdings (POAS) currently trades at $0.7670, while our estimate is $0.6938, 10% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.5203 (bear) to $0.8672 (bull), the price of $0.7670 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 21/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Phaos Technology Holdings reported revenue of 132K SGD in FY2026 versus 651K SGD in FY2023, a compound −41.2%/yr. Reported net income was −6.2M SGD in FY2026.

Key figures

Market cap $1.3M Micro · P/S ratio 9.71 · EPS (TTM) $−5.72 · Return on equity −369% · Return on assets (EBIT) −141% (4-year average) · Operating margin −10,748% · Revenue (TTM) 132K SGD · Revenue growth (YoY) −57.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 99% below its 52-week high and 5% above its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −10%, POAS screens richer than that median.

Fair Value

Bear $0.5203 Fair Value $0.6938 Bull $0.8672
Price $0.7670 · Downside -9.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 21/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 28
Do the profits arrive as real cash?
Financial strength 59
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 2
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−21.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−41.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−313.8% (2023) → −4,771.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

POAS screens overvalued: fair value 10% below the price. Compare with Abbott Laboratories, →

Compare Phaos Technology Holdings with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 21 · Bottom 25%
Fair Value upside −9.5% · Above median
Profitability
Return on assets −92.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −57.5% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.31× · Cheapest 25%
P/S (12 months) 12.45× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs POAS
DexCom, Inc DXCM $79.92 $89.18 +12% vs POAS
Stryker Corporation SYK $324.29 $358.30 +10% vs POAS
STERIS plc STE $257.12 $279.53 +9% vs POAS
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs POAS
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs POAS
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs POAS
Abbott Laboratories, ABT $110.46 $75.28 −32% vs POAS
Medtronic plc MDT $101.59 $65.61 −35% vs POAS
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs POAS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Phaos Technology Holdings: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Phaos Technology Holdings Fair Value". https://www.fairvalue-calculator.com/stock/POAS

Frequently asked questions

Is Phaos Technology Holdings (POAS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.6938 versus a price of $0.7670, about 10% lower (overvalued).
What is the fair value of POAS?
Our estimate for Phaos Technology Holdings is $0.6938 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.7670.
What is the quality score of POAS?
Phaos Technology Holdings has a Quality Score of 21/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Phaos Technology Holdings (POAS)?
Our calculated price target is the estimate of $0.6938 (as of Nov 10, 2026). Cautious scenario $0.5203, optimistic scenario $0.8672. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Phaos Technology Holdings stock forecast for 2026?
Our estimate puts fair value at $0.6938, about 10% lower versus a price of $0.7670 (overvalued). Cautious scenario $0.5203, optimistic scenario $0.8672. The calculation is refreshed regularly with new filings.
What is the revenue of Phaos Technology Holdings (POAS)?
Phaos Technology Holdings reported trailing-twelve-month revenue of about 132K SGD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Phaos Technology Holdings (POAS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Phaos Technology Holdings it is $0.6938 per share (as of Nov 10, 2026), against a price of $0.7670.
Is Phaos Technology Holdings stock overvalued or undervalued in 2026?
As of Nov 10, 2026, POAS trades above its calculated fair value: price $0.7670, fair value $0.6938, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of POAS?
No. The price is what the market pays today ($0.7670); the fair value is what the company's own numbers justify ($0.6938). For Phaos Technology Holdings the two are $0.0732 per share apart. That gap is exactly why we show both numbers side by side.
How much is Phaos Technology Holdings worth?
The market values Phaos Technology Holdings at about $1.3M (market capitalisation, as of Nov 10, 2026). Per share that is $0.7670; our models calculate a fair value of $0.6938 per share.
What do the bullish and bearish scenarios say about POAS?
Our models span a range for Phaos Technology Holdings: cautious scenario $0.5203, base $0.6938, optimistic $0.8672 per share (as of Nov 10, 2026, price $0.7670). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Phaos Technology Holdings (POAS)?
Balance-sheet figures for Phaos Technology Holdings (as of Nov 10, 2026): return on equity −369.0%, debt of 0.00 per unit of equity. They feed the Quality Score of 21/100, which measures business quality independently of the share price.
How far is POAS from its 52-week high?
Phaos Technology Holdings trades at $0.7670, about 99% below its 52-week high of $99.00 and 5% above the low of $0.7300 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.6938 is for.
Which stocks are comparable to Phaos Technology Holdings?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Phaos Technology Holdings stock attractive at the current price?
The data as of Nov 10, 2026: price $0.7670, calculated fair value $0.6938 (−10%), Quality Score 21/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Phaos Technology Holdings itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Phaos Technology Holdings (POAS)?
The closing price on Nov 10, 2026 was $0.7670. Our estimate is $0.6938, about 10% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Phaos Technology Holdings right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Phaos Technology Holdings

How large is the market capitalisation of Phaos Technology Holdings (POAS)?
The market capitalisation of Phaos Technology Holdings is $1.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Phaos Technology Holdings (POAS)?
The price-to-sales ratio of Phaos Technology Holdings is 9.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Phaos Technology Holdings (POAS)?
Earnings per share at Phaos Technology Holdings are $−5.72. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Phaos Technology Holdings (POAS)?
The return on equity (ROE) of Phaos Technology Holdings is −369% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Phaos Technology Holdings (POAS)?
On an EBIT basis the return on assets of Phaos Technology Holdings is −141% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Phaos Technology Holdings (POAS)?
The operating margin of Phaos Technology Holdings is −10,748% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Phaos Technology Holdings (POAS)?
Revenue at Phaos Technology Holdings is growing −57.5% versus a year earlier (3y avg −41.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Phaos Technology Holdings (POAS) generate?
The free cash flow of Phaos Technology Holdings is −10.9M SGD (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Phaos Technology Holdings (POAS) hold?
Phaos Technology Holdings holds more cash than debt, 311K SGD net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Phaos Technology Holdings in the live analysis

One click puts Phaos Technology Holdings on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.